Morepen Laboratories Limited has commenced commercial supplies under its ₹825 crore contract development and manufacturing organization (CDMO) mandate, marking a transition from validation to full-scale execution. The company completed its first dispatch, valued at approximately ₹50 crore, during Q1FY2026-27. This milestone supports Morepen's strategy to build a scalable CDMO platform and deepen customer partnerships in long-duration global manufacturing opportunities.

Managing Director's Statement

Sanjay Suri, Managing Director of Morepen Laboratories, stated that the teams have worked closely with the customer through validation, manufacturing readiness, and supply-chain planning. The focus now shifts to scaling up operations, expanding capacity, and pursuing additional customer and product opportunities within the CDMO segment.

Supply Schedule and Projections

Following the initial dispatch, Morepen expects to accelerate the program in the coming quarter. The company projects additional supplies of approximately ₹225 crore during Q2FY2026-27, contingent upon customer schedules and regulatory or commercial requirements. The table below outlines the supply schedule under the mandate:

Manufacturing Infrastructure Expansion

To support larger CDMO opportunities, Morepen Laboratories is strengthening its manufacturing infrastructure. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, with subsequent phases targeting expansion toward 800 KL and 1,000 KL. The commencement of commercial supplies under this mandate reinforces Morepen's objective to participate in global manufacturing opportunities across APIs, finished formulations, diagnostics, and consumer healthcare.

Morepen Laboratories Limited has elevated Sanjay Suri from Whole-time Director to Managing Director effective July 1, 2026. The Board of Directors approved this elevation on June 30, 2026, covering the balance tenure of his existing term ending August 12, 2028, subject to member approval within statutory timelines. This leadership change is intended to strengthen the company's management structure as it leverages over 40 years of operational history.

Consequent upon his elevation, Sanjay Suri will jointly oversee the management and operations of the company with Sushil Suri, Chairman & Managing Director. Their roles and responsibilities will be clearly defined and aligned to their respective areas of expertise to ensure streamlined governance and strategic execution.

The decision follows a recommendation by the Nomination and Remuneration Committee. Sanjay Suri brings over three decades of experience in the pharmaceuticals industry, with expertise spanning international sales and marketing, joint ventures, and statutory regulatory approvals including USFDA. His background also encompasses strategic planning, manufacturing operations, finance, accounts, and banking.

Sanjay Suri is a member of the promoter group and the brother of Sushil Suri. The company confirmed that he is not debarred from holding the office of Managing Director by any order passed by SEBI or other authorities. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Appointment Details